China A-share biopharma sector spiked intraday; Yiqiao Shenzhou surged to the daily limit in a straight-line move. Earlier Jin'an Protein and Baipusais hit limit-up; Nuoweizan, Wufan Biotech, Rongchang Biotech and Changchun Gaoxin also rose.

The Shanghai Stock Exchange's latest issuance and listing review update showed it accepted 54 IPO filings in Q2 versus 6 in Q1 (8x). Refinancing acceptances totaled 43 in Q2, up 72% QoQ, and M&A/restructuring filings reached 15, up 50% QoQ. The exchange concurrently stepped up on‑site supervision and tightened review standards; self‑regulatory enforcement concentrated on IPO filings and supervisory measures against issuers and intermediary personnel increased, with more responsible individuals subject to regulatory action.

France's June trade balance due in 10 minutes.